The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLVI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Ayele HT, Brunetti VC, Renoux C, Tagalakis V, Filion KB

Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials.

Thrombosis research 2021 03;199;123-131 — 2021 03 — 123-131

Glueck CJ, Goldenberg N, Wang P

Thromboembolism peaking 3 months after starting testosterone therapy: testosterone-thrombophilia interactions.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2018 Apr;66;733-738 — 2018 Apr — 733-738

Nguyen SM, Ko Ko N, Sattar AS, Gucuk Ipek E, Ali S

Pulmonary Embolism Secondary to Testosterone-Enhancing Herbal Supplement Use.

Cureus 2017 Aug 06;9;e1545 — 2017 Aug 06 — e1545

Glueck CJ, Prince M, Patel N, Patel J, Shah P, Mehta N, Wang P

Thrombophilia in 67 Patients With Thrombotic Events After Starting Testosterone Therapy.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 Sep;22;548-53 — 2016 Sep — 548-53